Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Alzheimer's Disease

  Free Subscription

Articles published in Nat Med

Retrieve available abstracts of 21 articles:
HTML format

Single Articles

    November 2022
    The long road to a cure for Alzheimer's disease is paved with failures.
    Nat Med. 2022;28:2228-2231.

  2. OSSENKOPPELE R, Pichet Binette A, Groot C, Smith R, et al
    Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
    Nat Med. 2022;28:2381-2387.
    PubMed     Abstract available

  3. Amyloid-beta and tau PET scans predict clinical progression in cognitively unimpaired people.
    Nat Med. 2022;28:2267-2268.

    September 2022

  4. Toward inflammation-free therapeutics in Alzheimer's disease.
    Nat Med. 2022 Sep 8. pii: 10.1038/s41591-022-01972.

  5. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022;28:1965.

  6. JUNG H, Lee SY, Lim S, Choi HR, et al
    Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein.
    Nat Med. 2022;28:1802-1812.
    PubMed     Abstract available

    August 2022
  7. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022 Aug 11. pii: 10.1038/s41591-022-01925.
    PubMed     Abstract available

    July 2022
  8. SCHINDLER SE, Karikari TK
    Comorbidities confound Alzheimer's blood tests.
    Nat Med. 2022 Jul 4. pii: 10.1038/s41591-022-01875.

  9. MIELKE MM, Dage JL, Frank RD, Algeciras-Schimnich A, et al
    Performance of plasma phosphorylated tau 181 and 217 in the community.
    Nat Med. 2022;28:1398-1405.
    PubMed     Abstract available

    February 2022
  10. O'LEARY K
    Mapping the mediators of Alzheimer's disease.
    Nat Med. 2022 Feb 28. pii: 10.1038/d41591-022-00037.

    September 2021
  11. PASCOAL TA, Benedet AL, Ashton NJ, Kang MS, et al
    Microglial activation and tau propagate jointly across Braak stages.
    Nat Med. 2021;27:1592-1599.
    PubMed     Abstract available

    Aducanumab: look before leaping.
    Nat Med. 2021;27:1499.

    Why aducanumab is important.
    Nat Med. 2021;27:1498.

    August 2021
  14. JABBARI E, Duff KE
    Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
    Nat Med. 2021;27:1341-1342.

    July 2021
    Dominantly inherited Alzheimer's disease: a compass for drug development.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01434.

    June 2021
  16. SALLOWAY S, Farlow M, McDade E, Clifford DB, et al
    A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Nat Med. 2021 Jun 21. pii: 10.1038/s41591-021-01369.
    PubMed     Abstract available

    Biomarkers for neurodegenerative diseases.
    Nat Med. 2021;27:954-963.
    PubMed     Abstract available

    May 2021
  18. PALMQVIST S, Tideman P, Cullen N, Zetterberg H, et al
    Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Nat Med. 2021 May 24. pii: 10.1038/s41591-021-01348.
    PubMed     Abstract available

    April 2021
  19. VOGEL JW, Young AL, Oxtoby NP, Smith R, et al
    Four distinct trajectories of tau deposition identified in Alzheimer's disease.
    Nat Med. 2021 Apr 29. pii: 10.1038/s41591-021-01309.
    PubMed     Abstract available

    January 2021
  20. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01251.

    November 2020
  21. ARNOLD C
    Post-hoc analysis could give new life to the Alzheimer's drug aducanumab.
    Nat Med. 2020 Nov 2. pii: 10.1038/d41591-020-00031.

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.